Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Fig. 2

Comparison of IFX SC1 versus VDZ for key efficacy outcomes in patients with Crohn’s disease. 1Results from the induction period were analysed for patients included in the IFX SC group who had received IFX IV induction therapy. Error bars show 95% CIs. CDAI-100: ≥ 100-point decrease in Crohn’s Disease Activity Index; CDAI-70: ≥ 70-point decrease in Crohn’s Disease Activity Index; CI: Confidence interval; IFX: Infliximab; IV: Intravenous; LOE: Lack of efficacy; SC: Subcutaneous; VDZ: Vedolizumab

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us